PubMed · 7964972
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
R T Dorr, D Lauper. 1994. Dosing error in protocol book.. https://doi.org/10.1200/jco.1994.12.11.2520
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
BACKGROUND: Survival of patients with locally advanced, unresectable (stage III), non-small-cell lung cancer treated with radiotherapy is poor. Trials of the addition of chemotherapy to radiotherapy have produced conflicting results. OBJECTIVE: To compare chemotherapy plus radiotherapy with radiotherapy alone in patients with stage III, non-small-cell lung cancer. DATA SOURCES: English-language journal articles published between 1987 and 1995 identified in a MEDLINE search. STUDY SELECTION: Randomized trials that reported survival after previously untreated patients received chemotherapy plus radiotherapy or radiotherapy alone were reviewed. DATA EXTRACTION: For all eligible articles, reported survival curves were used to determine the relative risk for death in each of 3 years. These data were combined to determine a pooled estimate of the relative risk for death at 1, 2, and 3 years. DATA SYNTHESIS: Fourteen articles reporting on a total of 2589 patients were reviewed. Compared with radiotherapy, the combination of chemotherapy and radiotherapy reduced the risk for death at 1 year (relative risk, 0.88 [95% Cl, 0.80 to 0.96]), 2 years (relative risk, 0.87 [Cl, 0.81 to 0.94]), and 3 years (relative risk, 0.83 [Cl, 0.77 to 0.90]). This corresponded to a mean gain in life expectancy of about 2 months. The magnitude of the treatment effect was similar when trials of concurrently and sequentially administered chemotherapy were considered separately. CONCLUSION: The addition of chemotherapy to radiotherapy improves survival in patients with locally advanced, unresectable, non-small-cell lung cancer. The absolute benefit is relatively small, however, and should be balanced against the increased toxicity associated with the addition of chemotherapy.
Chromosomal aberrations were examined in a breast cancer patient 11 years after cessation of cyclophosphamide methotraxate and 5-fluorouracil (CMF) therapy. This indicates that they may well be derived from a population of genetically damaged progenitor cells, from which abnormal and possibly malignant cell clones may have been generated, and a fraction of these randomly occurring chromosome rearrangements appear to be 'stable'.
Explore the source record for details and available documents.